Literature DB >> 23581553

Polymorphisms of survivin and its protein expression are associated with colorectal cancer susceptibility in Chinese population.

Xia-Bin Li1, Shi-Ning Li, Zhi-Hui Yang, Ling Cao, Fang-Lei Duan, Xing-Wang Sun.   

Abstract

To investigate the association of survivin -31G/C, -141G/C, and -241T/C polymorphisms with colorectal cancer (CRC) susceptibility and explore the mechanisms of the survivin polymorphism in CRC development. A case-control study was conducted of 275 CRC cases and 270 healthy controls. Polymorphisms of survivin -31G/C, -141G/C, and -241T/C were genotyped by polymerase chain reaction-restriction fragment length polymorphism. Survivin and Ki-67 expression was analyzed by immunohistochemistry by the Envision technique for the paraffin sections of 152 CRC. It showed that the -31G/C genotype and allele distribution were significantly different between the CRC cases and controls. The -31CC genotype and -31C allele were over-represented among the CRC cases. Compared with the CC genotype, the GC and GG genotypes had a significantly decreased risk of CRC (p=0.015). Survivin and Ki-67 expression of patients with the CC genotype was significantly higher than the patients with the GC and GG genotypes. In addition, a significantly positive correlation was found between expression of Survivin and Ki-67. There were no significant difference of the -141G/C and -241T/C polymorphism distributions among cases and controls. Survivin 31G/C may adjust the Survivin expression, and it might contribute to a risk of developing CRC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23581553      PMCID: PMC3651681          DOI: 10.1089/dna.2012.1912

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  27 in total

1.  Survivin SNP-carcinogen interactions in oral cancer.

Authors:  C J Weng; Y H Hsieh; M K Chen; C M Tsai; C W Lin; S F Yang
Journal:  J Dent Res       Date:  2012-02-08       Impact factor: 6.116

2.  Survivin-induced Aurora-B kinase activation: A mechanism by which APC mutations contribute to increased mitoses during colon cancer development.

Authors:  Tao Zhang; Jeremy Z Fields; Lynn Opdenaker; Tomas Otevrel; Emi Masuda; Juan P Palazzo; Gerald A Isenberg; Scott D Goldstein; Marc Brand; Bruce M Boman
Journal:  Am J Pathol       Date:  2010-11-05       Impact factor: 4.307

3.  Survivin promoter -31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis.

Authors:  Kshitij Srivastava; Anvesha Srivastava; Balraj Mittal
Journal:  Mol Biol Rep       Date:  2011-05-26       Impact factor: 2.316

4.  Evaluation of proliferating markers Ki-67, PCNA in gastric cancers.

Authors:  J Czyzewska; K Guzińska-Ustymowicz; A Lebelt; B Zalewski; A Kemona
Journal:  Rocz Akad Med Bialymst       Date:  2004

Review 5.  Apoptosis in the pathogenesis and treatment of disease.

Authors:  C B Thompson
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

Review 6.  Targeting survivin in cancer therapy.

Authors:  Marzia Pennati; Marco Folini; Nadia Zaffaroni
Journal:  Expert Opin Ther Targets       Date:  2008-04       Impact factor: 6.902

Review 7.  Survivin, cancer networks and pathway-directed drug discovery.

Authors:  Dario C Altieri
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

8.  Symmetric division of cancer stem cells--a key mechanism in tumor growth that should be targeted in future therapeutic approaches.

Authors:  B M Boman; M S Wicha; J Z Fields; O A Runquist
Journal:  Clin Pharmacol Ther       Date:  2007-04-25       Impact factor: 6.875

9.  Survivin -31G/C promoter polymorphism and sporadic colorectal cancer.

Authors:  Maria Gazouli; Nikolaos Tzanakis; George Rallis; George Theodoropoulos; Ioannis Papaconstantinou; Alkiviadis Kostakis; Nicholas P Anagnou; Nikolaos Nikiteas
Journal:  Int J Colorectal Dis       Date:  2008-10-23       Impact factor: 2.571

10.  Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications.

Authors:  S Mohamed; K Yasufuku; T Nakajima; K Hiroshima; M Chiyo; S Yoshida; M Suzuki; Y Sekine; K Shibuya; G Agamy; H El-Shahhat; T Fujisawa; I Yoshino
Journal:  Eur Respir J       Date:  2008-08-20       Impact factor: 16.671

View more
  9 in total

1.  Correlation between survivin genetic polymorphisms and lung cancer susceptibility.

Authors:  Guifang Guo; Qiang Zhang; Zhengang Yu; Junjuan Li; Zhaolei Ding; Juan Li; Wei Tan
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

2.  Survivin -31 G/C polymorphism might contribute to colorectal cancer (CRC) risk: a meta-analysis.

Authors:  Linhua Yao; Yi Hu; Zhongmin Deng; Jingjing Li
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 3.  Association between survivin -31G>C polymorphism and cancer risk: meta-analysis of 29 studies.

Authors:  Qin Qin; Chi Zhang; Hongcheng Zhu; Xi Yang; Liping Xu; Jia Liu; Jing Lu; Liangliang Zhan; Hongyan Cheng; Xinchen Sun
Journal:  J Cancer Res Clin Oncol       Date:  2014-02       Impact factor: 4.553

4.  Survivin rs9904341 (G>C) polymorphism contributes to cancer risk: an updated meta-analysis of 26 studies.

Authors:  Lei Xu; Xin Zhou; Lin Xu; Rong Yin
Journal:  Tumour Biol       Date:  2013-10-05

5.  Polymorphisms of BIRC5 Gene is Associated with Chronic HBV Infection in Iranian Population.

Authors:  Bita Moudi; Zahra Heidari; Hamidreza Mahmoudzadeh-Sagheb
Journal:  Indian J Clin Biochem       Date:  2019-01-02

Review 6.  Survivin and angiotensin-converting enzyme polymorphisms with risk of colorectal cancer: a systematic review and meta-analysis.

Authors:  Xile Zhou; Caizhao Lin
Journal:  World J Surg Oncol       Date:  2015-02-07       Impact factor: 2.754

7.  Regulation of Survivin Isoform Expression by GLI Proteins in Ovarian Cancer.

Authors:  Diana Trnski; Maja Gregorić; Sonja Levanat; Petar Ozretić; Nikolina Rinčić; Tajana Majić Vidaković; Držislav Kalafatić; Ivana Maurac; Slavko Orešković; Maja Sabol; Vesna Musani
Journal:  Cells       Date:  2019-02-06       Impact factor: 6.600

8.  Clinical significance of survivin expression in patients with urothelial carcinoma.

Authors:  Hsin-An Chen; Chih-Ming Su; Hsiao-Yen Hsieh; Chun-Liang Tung; Cheng-Da Hsu; Yuan-Hung Wang; Cheng-Huang Shen
Journal:  Dis Markers       Date:  2014-02-05       Impact factor: 3.434

9.  Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer.

Authors:  Michał Szczyrek; Radosław Mlak; Aneta Szudy-Szczyrek; Kamila Wojas-Krawczyk; Karolina Kędziora; Janusz Milanowski
Journal:  Cells       Date:  2022-03-10       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.